Fineline Cube

Follow:
14486 Articles
Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
CompanyDeals

Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus

Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
CompanyDrug

Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy

Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval
CompanyDrug

Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China
CompanyDrug

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China

Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3
CompanyDrug

Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3

Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
CompanyDeals

Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles

Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
CompanyDeals

Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs

ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs
CompanyDeals

ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs

AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
CompanyDrug

AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma

Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
CompanyDeals

Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs

Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug
CompanyDrug

Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug

FDA Unveils RDEP to Accelerate Rare Disease Therapy Development
Policy / Regulatory

FDA Unveils RDEP to Accelerate Rare Disease Therapy Development